Patents Examined by David K O'Dell
  • Patent number: 11512066
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: November 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • Patent number: 11505549
    Abstract: A novel process for preparation of Deutetrabenazine ((RR, SS)-1,3,4,6,7-11b-Hexahydro-9,10-di(methoxy-d6)-3-(2-methylpropyl)-2H-benzo [a] quinolizin-2-one) of formula I comprises of methylation of N-(2-(3,4-dihydroxy-phenyl)-ethyl)-formamide compound of formula III with deuteriated methanol (CD3OD or CD3OH) to obtain d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide compound of formula IV; cyclization of d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide in presences of dehydrating agent to obtain d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V; reacting d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V with 2-acetyl-N,N,N,4-tetramethyl-1-pentanaminium iodide compound of formula VI.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 22, 2022
    Inventor: Lakshmi Prasad Alaparthi
  • Patent number: 11497813
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a conjugate of bortezomib (Btz) and a bisphosphonate to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 15, 2022
    Assignee: BIOVINC, LLC
    Inventors: Frank Ebetino, Robert Boeckman, Lianping Xing, Lifeng Xiao, Brendan Boyce
  • Patent number: 11492365
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: November 8, 2022
    Assignee: GASHERBRUM BIO, INC.
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Hui Lei, Andrew Jennings
  • Patent number: 11479565
    Abstract: The present invention relates to a process for preparing substituted imidazole derivatives of the formula (II) from compounds of the formula (I) via intermediates of the formula (IVa) or (IVb) in which the structural elements shown in the formulae (I), (II), (IVa) and (IVb) have the meanings given in the description. Furthermore, the invention relates to the intermediates of the formulae (IVa) and (IVb).
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: October 25, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: Matthieu Willot, Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Marc Mosrin, David Wilcke
  • Patent number: 11472832
    Abstract: Provided herein are synthetic analogs of withanolide natural products and their pharmaceutical uses in treating neurodegenerative diseases.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: October 18, 2022
    Assignees: ARNA Therapeutics Inc., Universite Laval
    Inventors: Anthony A. Shaw, Jean-Pierre Julien, Agnes H. Chan
  • Patent number: 11472769
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 18, 2022
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Qing Xu
  • Patent number: 11465990
    Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 11, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
  • Patent number: 11453670
    Abstract: The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 27, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Qiang Zhang
  • Patent number: 11453640
    Abstract: Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: September 27, 2022
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin R. Smith, Gary E. Schiltz, Rama K. Mishra, Kristen Stoltz
  • Patent number: 11447506
    Abstract: The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 20, 2022
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Minhua Chen, Yanfeng Zhang, Fei Lu, Nan Xia, Xiaoyu Zhang
  • Patent number: 11440884
    Abstract: The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: September 13, 2022
    Assignee: ACADIA PHARMACEUTICALS INC.
    Inventors: Ethan S. Burstein, Roger Olsson, Karl Erik Jansson, Niklas Patrik Sköld, Larisa Yudina Wahlström, Björn Gustav Borgström, Henrik Von Wachenfeldt, Magnus Gustav Wilhelm Bergner
  • Patent number: 11434257
    Abstract: This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: September 6, 2022
    Assignee: DepYmed Inc.
    Inventors: Michael McLane, Inez Ruiz-White, W. Lee Maloy, Henry R. Wolfe
  • Patent number: 11427544
    Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 30, 2022
    Assignees: TAIPEI MEDICAL UNIVERSITY, NATIONAL TAIWAN UNIVERSITY
    Inventors: Che-Ming Teng, Jing-Ping Liou, Shiow-Lin Pan, Chia-Ron Yang
  • Patent number: 11420940
    Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-I with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of in-flammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: August 23, 2022
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Gianluca Mariano Enrico Papeo, Mikhail Yurievitch Krasavin, Paolo Orsini, Alessandra Scolaro
  • Patent number: 11420977
    Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. heptacellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: August 23, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott Edward Schaus, Ulla Hansen, Hang Gyeong Chin
  • Patent number: 11414396
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: August 16, 2022
    Assignees: Exelixis, Inc., Genentech, Inc.
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
  • Patent number: 11414442
    Abstract: Methods of treating vascular leak, vascular inflammation, angiogenesis, ocular disorders, and/or inflammatory disorders in a patient are provided. The methods can include administering an ADP-ribosylation factor 6 (ARF6) inhibitor to the patient. The present disclosure also relates to new chemical entities and pharmaceutical compositions including ARF6 inhibitors. The ARF6 inhibitor may be a prodrug of an ARF6 inhibitor.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 16, 2022
    Assignee: Navigen, Inc.
    Inventors: Ashok Bajji, Kirill Ostanin, Alan Mueller, Damon Papac
  • Patent number: 11406624
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 9, 2022
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Kai Liu, Jun Pan, Wenqing Yao, Qinda Ye
  • Patent number: 11406629
    Abstract: Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 9, 2022
    Assignee: Celgene Corporation
    Inventors: G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer